ClinicalTrials.gg
CompletedNCT01447485Updated Dec 21, 2020

Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients

A Phase 1 interventional study of Valsartan (VAL489) in Hypertension, Chronic Kidney Disease and Nephrotic Syndrome, sponsored by Novartis Pharmaceuticals. Completed at 2 sites in Japan. Open to participants aged 6 Years to 14 Years. Per ClinicalTrials.gov, last updated 2020-12-21.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
6 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
133rd of 139
12 · median 198
Started
2011
with 6 others
Phase 1
10 of 140
none open now
Registered
115th of 140
by date
Lead sponsor
19 of 140
Novartis Pharmaceuticals

Among the 140 studies testing valsartan in Hypertension, this one is the 133rd largest by enrollment of the 139 interventional ones that give a count, is one of 7 that started in 2011, is one of 10 in phase 1, and was the 115th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 6 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

This study will assess the pharmacokinetics and safety following single dose of valsartan in Japanese pediatric patients with hypertension, chronic kidney disease, or nephrotic syndrome.

03

Conditions studied

  • Hypertension
  • Chronic Kidney Disease
  • Nephrotic Syndrome

Keywords

  • Hypertension, chronic kidney disease
  • nephrotic syndrome
  • pharmacokinetics
04

Who can participate

Ages eligible
6 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese pediatric patients with hypertension, chronic kidney disease, or nephrotic syndrome

Exclusion criteria

Exclusion Criteria:

  • \< 30 mL/min/1.73 m2
  • Inability to safely tolerate the temporary discontinuation of concomitant antihypertensive medications (expect amlodipine or atenolol) from 24 hours prior to study drug administration to study completion.
  • Inability to safely tolerate the temporary discontinuation of any drug known or suspected to effect hepatic or renal clearance capacity from 24 hours prior to study drug administration to study completion (this includes drugs that are known to cause induction or inhibition of hepatic enzymes).

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Valsartan 20 mg or 40 mg

    Drug: Valsartan (VAL489)

Interventions

06

What researchers measure

Primary outcomes

  1. AUC of valsartan in plasma

    Time frame: Up to 24 hours post-dose

  2. Cmax of valsartan in plasma

    Time frame: Up to 24 hours post-dose

  3. Tmax of valsartan in plasma

    Time frame: Up to 24 hours post-dose

  4. T1/2 of valsartan in plasma

    Time frame: Up to 24 hours post-dose

  5. CL/F of valsartan in plasma

    Time frame: Up to 24 hours post-dose

Secondary outcomes

  1. ECG evaluations

    Time frame: 24 hours post-dose

  2. Standard clinical laboratory evaluations

    Time frame: 24 hours post-dose

  3. Vital signs

    Time frame: 2, 4, and 24 hours post-dose

  4. Physical examination

    Time frame: 24 hours post-dose

  5. Number and severity of adverse events

    Time frame: Up to 24 hours post-dose

07

Study locations

2 sites
  • Novartis Investigative Site
    Aichi, Japan
  • Novartis Investigative Site
    Tokyo, Japan
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2011
First posted
Oct 6, 2011
Start
Aug 2011
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Last update
Dec 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01447485
Responsible party
Sponsor
First posted
Oct 6, 2011
Start date
Aug 2011
Primary completion
Oct 2011
Completion
Oct 2011
Last update
Dec 21, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valsartan

Start the discussion